Table 2 Treatment effect of simvastatin versus placebo on primary and secondary outcomes
Statin, n = 2753 | Statin-free, n = 866 | Statin vs. Statin-free | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Events, n(%) | Annual rate, %/y | Events, n(%) | Annual rate, %/y | Unadjusted | Adjusted* | Adjusted# | ||||
Hazard Ratio, (95%CI) | p | Hazard Ratio, (95%CI) | p | Hazard Ratio, (95%CI) | p | |||||
Chronic kidney disease | 433(15.7) | 3.9 | 134(15.5) | 4.9 | 0.75 (0.62,0.91) | < 0.01 | 0.54 (0.43,0.67) | < 0.01 | 0.29(0.27,0.31) | < 0.01 |
Renal failure | 72(2.6) | 0.56 | 19(2.2) | 0.53 | 1.06 (0.64,1.75) | 0.83 | 1.14 (0.65,2.01) | 0.65 | 0.53(0.44,0.65) | < 0.01 |
Renal function decline | 1322(48) | 15.5 | 416(48) | 19.5 | 0.82 (0.73,0.91) | < 0.01 | 0.87 (0.79,0.99) | 0.04 | 0.54(0.52,0.56) | < 0.01 |
Microalbuminuria | 456(16.6) | 6.1 | 87(10.0) | 4.4 | 1.40 (1.11,1.76) | < 0.01 | 1.31 (1.02,1.68) | 0.04 | 0.81(0.73,0.89) | < 0.01 |
Macroalbuminuria | 189(6.9) | 1.7 | 38(4.4) | 1.3 | 1.37 (0.97,1.94) | 0.08 | 1.25 (0.85,1.83) | 0.26 | 1.05(0.91,1.22) | 0.49 |